For example, in lung cancer, miRNA panels derived from liquid biopsies can differentiate benign from malignant lesions (131), while in prostate cancer, lncRNAs such as PCA3 have been established as clinical diagnostic markers (132). This evidence concerns the gene PCA3 and prostate carcinoma.